Sildenafil aggravates adriamycin-induced testicular toxicity in rats; a preliminary investigation

Drug Chem Toxicol. 2023 Mar;46(2):219-225. doi: 10.1080/01480545.2021.2018455. Epub 2021 Dec 29.

Abstract

Male reproductive toxicity is a well-established side effect of the chemotherapeutic drug adriamycin (ADR). Sildenafil (SIL) is a phosphodiesterase inhibitor known to enhance the chemosensitivity of cancer cells to ADR. However, there is a scarcity of information on the effect of SIL on ADR-induced testicular toxicity. In this study, SIL (5, 10, or 20 mg/kg/day) was administered to male rats for 7 days, followed by a single intraperitoneal injection of ADR (20 mg/kg) on day 7. Control rats received either ADR, SIL, or normal saline for 7 days. Epididymal sperm were collected from the testes to assess the effects on sperm quality, quantity, and serum testosterone concentration was also determined. ADR treatment caused a decrease in sperm motility and elevated the percentage of sperms with tail defects which worsened in combination with SIL (20 mg/kg). Furthermore, ADR alone or in combination with SIL dose-dependently increased total sperm abnormalities. SIL (20 mg/kg) plus ADR also decreased sperm count and lowered testosterone level compared to ADR-only rats. In conclusion, exposure of rats to SIL before ADR treatment has the potential to worsen ADR-induced testicular toxicity.

Keywords: Sildenafil; adriamycin; aggravates; testicular toxicity.

MeSH terms

  • Animals
  • Doxorubicin* / toxicity
  • Male
  • Rats
  • Semen
  • Sildenafil Citrate / toxicity
  • Sperm Motility
  • Testis*
  • Testosterone

Substances

  • Doxorubicin
  • Sildenafil Citrate
  • Testosterone